| |
著者: Kazuhiro Kawaguchi, Hiroo Inamura, Yasuhiro Abe, Hidehiro Koshu, Emi Takashita, Yasushi Muraki, Yoko Matsuzaki, Hidekazu Nishimura, Hitoshi Ishikawa, Akira Fukao, Seiji Hongo, Masaru Aoyagi
雑誌名: Laryngoscope. 2007 Jan;117(1):147-56. doi: 10.1097/01.mlg.0000248737.65607.9e.
Abstract/Text
OBJECTIVES: To determine whether reactivation of herpes simplex virus (HSV) type 1 or varicella-zoster virus (VZV) is the main cause of Bell's palsy and whether antiviral drugs bring about recovery from Bell's palsy.
STUDY DESIGN: Randomized, multicenter, controlled study.
METHODS: One hundred fifty patients with Bell's palsy were enrolled in this study. The patients were randomly assigned to a prednisolone group or a prednisolone-valacyclovir group, in whom virologic examinations for HSV-1 and VZV were performed by simple randomization scheme in sealed envelopes. The recovery rates among various groups were analyzed using the Kaplan-Meier method and the Cox proportional hazards model.
RESULTS: Reactivation of HSV-1, VZV, and both viruses was detected in 15.3%, 14.7%, and 4.0% of patients, respectively. There was no significant difference in recovery rates between the prednisolone group and the prednisolone-valacyclovir group, although recovery in the patients with HSV-1 reactivation tended to be higher in the prednisolone-valacyclovir group than in the prednisolone group. There was a significant difference in recovery among age groups and between individuals with complete and incomplete paralysis.
CONCLUSIONS: Reactivation of HSV-1 or VZV was observed in 34% of the patients with Bell's palsy. The effect of combination therapy with prednisolone and valacyclovir on recovery was not significantly higher than that with prednisolone alone.
PMID 17202945 Laryngoscope. 2007 Jan;117(1):147-56. doi: 10.1097/01.mlg.0000248737.65607.9e.
|
